Bioxytran, Inc.
BIXT
$0.1567
-$0.0054-3.33%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 53.79% | -51.56% | |||
| Depreciation & Amortization | 93.33% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 41.27% | -43.08% | |||
| Operating Income | -41.27% | 43.08% | |||
| Income Before Tax | -31.73% | 40.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.73% | 40.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.34% | 40.70% | |||
| EBIT | -41.27% | 43.08% | |||
| EBITDA | -41.05% | 43.19% | |||
| EPS Basic | -74.19% | 16.22% | |||
| Normalized Basic EPS | -247.37% | 17.39% | |||
| EPS Diluted | -74.19% | 16.22% | |||
| Normalized Diluted EPS | -247.37% | 17.39% | |||
| Average Basic Shares Outstanding | -26.47% | -28.43% | |||
| Average Diluted Shares Outstanding | -26.47% | -28.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||